The Administrative Core, led by Dr. Frederick Lang (Director) and Dr. Juan Fueyo (Co-Director), provides critical centralized administrative support to ensure the success of the entire SPORE. The specific objectives of the Administrative Core are to: Oversee and administer all SPORE activities. Oversee all SPORE Projects and Core activities. Oversee the Developmental Research and Career Development Programs. Promote integration and communication between the SPORE, the Brain Cancer Program, and the Cancer Center Support Grant. Ensure compliance with institutional, governmental, and NCI regulations. Communicate and consult with the NCI program officer and other staff to ensure timely preparation and submission of reports, publications, and Important events that affect management of the SPORE. Oversee and administer all fiscal and budgetary activities of the SPORE. Manage and provide quality assurance, including data quality control, in cooperation with the Biostatistics and Bioinformatics Core. Coordinate meetings of the Executive Committee, Internal and External Advisory Boards, monthly investigator meetings, lectures, and symposia. Ensure compliance with and improvement of policies for recruitment of women and minorities. Coordinate with other Brain Cancer SPORE programs and investigators, as well as other organ site SPORE programs, to promote research communication in meetings, distribution of materials, electronic communications, and evaluation of progress reports.
The Administrative Core provides the support and infrastructure for research and financial oversight;clear and open communications among all SPORE investigators, patient advocates, and developmental awardees;and regulatory monitoring to optimize the successful outcome of the translational research in brain cancer.
|Ji, Haitao; Lee, Jong-Ho; Wang, Yugang et al. (2016) EGFR phosphorylates FAM129B to promote Ras activation. Proc Natl Acad Sci U S A 113:644-9|
|Hodges, Tiffany R; Ferguson, Sherise D; Heimberger, Amy B (2016) Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol 5:175-86|
|Zhou, Aidong; Lin, Kangyu; Zhang, Sicong et al. (2016) Nuclear GSK3Î² promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22. Nat Cell Biol 18:954-66|
|Ohtsuka, Masahisa; Ling, Hui; Ivan, Cristina et al. (2016) H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Î²-Catenin Signaling in Colorectal Cancer. EBioMedicine :|
|Shah, Maitri Y; Ferrajoli, Alessandra; Sood, Anil K et al. (2016) microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine 12:34-42|
|Lee, J; Jain, R; Khalil, K et al. (2016) Texture Feature Ratios from Relative CBV Maps of Perfusion MRI Are Associated with Patient Survival in Glioblastoma. AJNR Am J Neuroradiol 37:37-43|
|Gabrusiewicz, Konrad; Rodriguez, Benjamin; Wei, Jun et al. (2016) Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight 1:|
|Xue, Jianfei; Zhou, Aidong; Wu, Yamei et al. (2016) miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res 76:4293-304|
|Chen, Yaohui; Li, Yu; Xue, Jianfei et al. (2016) Wnt-induced deubiquitination FoxM1 ensures nucleus Î²-catenin transactivation. EMBO J 35:668-84|
|Park, Soon Young; Piao, Yuji; Thomas, Craig et al. (2016) Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma. Oncotarget 7:26793-805|
Showing the most recent 10 out of 176 publications